Moreover, a TCGA database analysis showed that KLHL42 mRNA was amplified in pancancer contexts, especially in breast cancer, bladder cancer and prostate cancer (Supplementary Fig. 4b), and was significantly correlated with MYC protein levels in bladder cancer (Supplementary Fig. 4c). Here, KLHL42 is linked to prostate carcinoma.